Open AccessLidocaine 700 mg medicated plaster for postherpetic neuralgia: real-world data from the German Pain e-Registry
Author(s) -
Michael A. Überall,
Mariëlle Eerdekens,
Els Hollanders,
Irmgard Bösl,
Ingo Sabatschus
Publication year - 2022
Publication title -
pain management
Language(s) - English
Resource type - Journals
eISSN - 1758-1877
pISSN - 1758-1869
DOI - 10.2217/pmt-2021-0022
Subject(s) - postherpetic neuralgia , medicine , tolerability , shingles , adverse effect , lidocaine , anesthesia , neuralgia , discontinuation , surgery , neuropathic pain , virus , virology
Aim: To provide real-world evidence for the effectiveness and tolerability of lidocaine 700 mg medicated plaster (LMP) compared with oral systemic first-line medications (OSM) in postherpetic neuralgia treatment. Patients & methods: Retrospective cohort study in patients refractory to at least one recommended OSM (single drug or a combination of drugs) using anonymized routine medical care data from the German Pain e-Registry. A matched pair approach using propensity score matching was employed. Results: A total of 1711 data sets of postherpetic neuralgia patients were identified per treatment group. The majority (>60%) had experienced pain for more than a year and reported a high burden of pain and reduced quality of life. Six months of LMP treatment provided significantly greater pain reductions, improvements in pain-related impairments and quality of life than OSM treatment (p < 0.001 for all parameters). Drug-related adverse events and treatment discontinuation due to drug-related adverse events also occurred less frequently under LMP treatment (p < 0.001). Conclusion: These real-world data confirm the effectiveness and good tolerability of LMP under routine medical care. The treatment was significantly more effective when compared with first-line oral systemic medications.